$CDNA

CareDx, Inc.

CareDx is a precision medicine company serving transplant patients, clinicians and transplant centers. It provides non-invasive molecular testing for heart, kidney and lung transplant recipients, along with laboratory products, digital health technologies, patient support and specialized pharmacy services. Its commercial testing services include AlloMap Heart and AlloSure tests for transplant surveillance, as well as testing for hematopoietic cell transplant recipients and cell therapy patients. Laboratory products help match organ or stem cell donors with recipients and support post-transplant monitoring. Digital and patient offerings include transplant workflow and referral software, quality and waitlist support, medication adherence tools, remote monitoring and pharmacy care. CareDx earns money by providing testing services, selling laboratory products and software, and offering pharmacy and other patient and center services. It also partners with pharmaceutical and biopharmaceutical companies on testing and research. The company operates as one reportable segment and is headquartered in Brisbane, California, with other primary operations in Omaha, Nebraska, and Stockholm, Sweden.

4
0
0
—
$6.4M
Kennedy Keith
100%
See all $CDNA insider activity →
Low

Goldberg Michael sold $1.1M of CDNA

Goldberg Michael sold 13,800 shares of CareDx, Inc. (CDNA) at an average of $79.15 ($78.32–$79.85, $1.09M total) across 3 trades on 2026-11-12 under a Rule 10b5-1 trading plan.

Piper Sandler initiates CareDx stock coverage with overweight rating

Piper Sandler initiated coverage on CareDx (CDNA) with an overweight rating and $100 price target, citing growth potential. The stock trades at $80.77, up 382% over the past year. The firm expects mid-teens to 20% growth in transplant business and 30%-40% annual growth for NavDx. CareDx reported Q3 2026 earnings of $0.70 EPS and $139M revenue, raising its full-year outlook. BTIG and Canaccord also raised their price targets to $92 and $99, respectively, maintaining Buy ratings.

Kennedy Keith sold $4.8M of CDNA

Kennedy Keith (CFO & COO) sold 61,961 shares of CareDx, Inc. (CDNA) at an average of $77.82 ($76.55–$83.60, $4.82M total) across 8 trades on 2026-11-05 under a Rule 10b5-1 trading plan.

CDNA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CDNA (CareDx, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.

Recent CDNA coverage spans financial news, earnings and insider activity.

In the last 30 days, CDNA insiders filed 16 SEC Form 4 transactions — no purchases and 16 sales ($6.4M). The most active reporter was Kennedy Keith, CFO & COO, with 10 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving CDNA

AlphAI scores every news story that mentions CDNA with an AI model for sentiment and relevance, and aggregates insider trades from CareDx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CDNA

Score

Piper Sandler initiates CareDx stock coverage with overweight rating

Piper Sandler initiated coverage on CareDx (CDNA) with an overweight rating and $100 price target, citing growth potential. The stock trades at $80.77, up 382% over the past year. The firm expects mid-teens to 20% growth in transplant business and 30%-40% annual growth for NavDx. CareDx reported Q3 2026 earnings of $0.70 EPS and $139M revenue, raising its full-year outlook. BTIG and Canaccord also raised their price targets to $92 and $99, respectively, maintaining Buy ratings.

CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know

CareDx (CDNA) was upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates, which could positively impact its stock price. The company is expected to earn $1.73 per share for the fiscal year ending December 2026, with the Zacks Consensus Estimate increasing 110.6% over the past three months. The upgrade places CareDx in the top 5% of Zacks-covered stocks.

Related tickers